Skip to content
Peptigraph home

Bimagrumab Phase 2 trial (NCT06643728)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 2
Status
Active, not recruiting
Enrolment
252
actual
Start
21 Oct 2024 (actual)
Primary completion
16 Jan 2026 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT06643728 study arms
ArmTypeInterventionsDescription
Part A: Bimagrumab Dose 2 + Tirzepatide PlaceboExperimentalDrug: Bimagrumab; Drug: Tirzepatide PlaceboParticipants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC
Part A: Bimagrumab Placebo + Tirzepatide Dose 1Active comparatorDrug: Tirzepatide; Drug: Bimagrumab PlaceboParticipants will receive bimagrumab placebo SC and tirzepatide SC
Part A: Bimagrumab Placebo + Tirzepatide Dose 2Active comparatorDrug: Tirzepatide; Drug: Bimagrumab PlaceboParticipants will receive bimagrumab placebo SC and tirzepatide SC
Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part A: Bimagrumab Placebo + Tirzepatide PlaceboPlacebo comparatorDrug: Bimagrumab Placebo; Drug: Tirzepatide PlaceboParticipants will receive bimagrumab placebo SC and tirzepatide placebo SC
Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1ExperimentalDrug: Bimagrumab; Drug: TirzepatideParticipants will receive bimagrumab SC and tirzepatide SC
Part B: Bimagrumab Dose 1 + Tirzepatide PlaceboExperimentalDrug: Bimagrumab; Drug: Tirzepatide PlaceboParticipants will receive bimagrumab SC and tirzepatide placebo SC
Part B: Bimagrumab Placebo + Tirzepatide PlaceboPlacebo comparatorDrug: Bimagrumab Placebo; Drug: Tirzepatide PlaceboParticipants will receive bimagrumab placebo SC and tirzepatide placebo SC
Endpoints

Primary endpoint

NCT06643728 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 24
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06643728 secondary outcomes
MeasureTime frame
Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA)Baseline, Week 24, Week 48
Change from Baseline in Body WeightBaseline, Week 24, Week 48
Percentage of Participants Achieving ≥5% Body Weight ReductionBaseline, Week 24, Week 48
Percentage of Participants Achieving ≥10% Body Weight ReductionBaseline, Week 24, Week 48
Percentage of Participants Achieving ≥15% Body Weight ReductionBaseline, Week 24, Week 48
Change from Baseline in Waist CircumferenceBaseline, Week 24, Week 48
Change from Baseline in Body Mass Index (BMI)Baseline, Week 24, Week 48
Change from Baseline in Waist-to-Height Ratio (WHtR)Baseline, Week 24, Week 48
Percent Change from Baseline in Visceral Adipose Tissue (VAT)Baseline, Week 24, Week 48
Percent Change from Baseline in Total Body Lean Mass by DXABaseline, Week 24, Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.